Purchase of glassia , 1000MG vials, from limited source baxalta US INC.:1276806 [pots: 20-010648]

Ended Awarded Last action

Contract number
75N90020F00071
Awardee
Awarding agency
Obligated
$10,560

Award facts

Contract value 100% obligated
$10,560.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
325412 Pharmaceutical Preparation Manufacturing
PSC
6505 Drugs And Biologicals
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price
Place of performance
Deerfield, IL 60015, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

About this award

Written by GovTribe AI ·

The NIH Clinical Center issued a $10,560 delivery order to Baxalta US Inc. on June 8, 2020, for 1,000 mg vials of Glassia under the GSA Pharmaceuticals and Drugs schedule (FSS-61-IB).

The order is priced on a firm fixed price basis. Place of performance is Deerfield, IL. The order is due for ultimate completion on June 10, 2020. Glassia is an alpha 1-proteinase inhibitor used in treating alpha-1 antitrypsin deficiency.

Quick answers

Who was awarded contract 75N90020F00071?

75N90020F00071 was awarded to Baxalta US Inc. by NIH Clinical Center (National Institutes of Health) on June 8, 2020.

How much is contract 75N90020F00071 worth?

The government has obligated $10,560 on 75N90020F00071.

Is contract 75N90020F00071 an order under another contract?

Yes. 75N90020F00071 is a delivery order under V797P2140D, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).

Was contract 75N90020F00071 competed?

The extent of competition for 75N90020F00071 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login